What is TRDA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.22B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TRDA?

P/E (TTM) is n/a and 52-week range is $5.15 to $16.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TRDA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TRDA?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-15.24B, EPS (TTM) near $-3.97 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Entrada Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 38.8M shares outstanding, ISIN US29384C1080 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Entrada Therapeutics Inc

$TRDA

Health Care · Biotechnology

IR Run Scenarios

$5.67

+2.53%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2021-10-29. The firm is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The firm is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The firm has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Employees

152

Website

www.entradatx.com/

IPO

2021-10-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)